These results provided bioinformatics-based evidence for the application of NLRP1/NLRP3 in predicting prognosis and selecting the appropriate immunotherapy in patients with GC and improved our understanding of the roles of NLRP1/NLRP3 in the GC regulatory network. This evidence concerns the gene NLRP1 and gastric cancer.